PHARMACOECONOMIC ANALYSIS OF HIV/AIDS MANAGEMENT
Table Of Contents
Chapter ONE
INTRODUCTION
- 1.1Introduction
- 1.2Background of Study
- 1.3Problem Statement
- 1.4Objective of Study
- 1.5Limitation of Study
- 1.6Scope of Study
- 1.7Significance of Study
- 1.8Structure of the Research
- 1.9Definition of Terms
Chapter TWO
LITERATURE REVIEW
- 2.1Overview of HIV/AIDS
- 2.2Epidemiology of HIV/AIDS
- 2.3Global Strategies for HIV/AIDS Management
- 2.4Pharmacological Interventions for HIV/AIDS
- 2.5Economic Impact of HIV/AIDS
- 2.6Cost-Effectiveness Analysis in Healthcare
- 2.7Health Economics and HIV/AIDS
- 2.8Socioeconomic Factors affecting HIV/AIDS Management
- 2.9Access to HIV/AIDS Treatment
- 2.10Innovations in HIV/AIDS Management
Chapter THREE
RESEARCH METHODOLOGY
- 3.1Research Design and Methodology
- 3.2Study Population and Sampling Techniques
- 3.3Data Collection Methods
- 3.4Data Analysis Techniques
- 3.5Ethical Considerations
- 3.6Pilot Study
- 3.7Questionnaire Design
- 3.8Statistical Tools Used
Chapter FOUR
DATA PRESENTATION AND ANALYSIS
- 4.1Demographic Characteristics of Participants
- 4.2Health Outcomes of HIV/AIDS Management
- 4.3Economic Analysis of HIV/AIDS Treatment
- 4.4Comparison of Treatment Modalities
- 4.5Patient Adherence to Treatment
- 4.6Healthcare Resource Utilization
- 4.7Cost-Effectiveness Analysis Results
- 4.8Recommendations for HIV/AIDS Management
Chapter FIVE
SUMMARY, CONCLUSION AND RECOMMENDATIONS
- 5.1Summary of Findings
- 5.2Conclusion
- 5.3Implications of the Study
- 5.4Recommendations for Future Research
- 5.5Contribution to Healthcare Policy
Project Abstract
<p> </p><p>The HIV/AIDS <a target="_blank" rel="nofollow" href="https//www.modishproject.com/design-implementation-line-medical/">pandemic</a> has resulted in mortality surge and life expectancy drop throughout the world. Developing countries are mostly affected due to their limited health care system and resources to handle the increasing costs of <a target="_blank" rel="nofollow" href="https//www.modishproject.com/epidemiology-mucormycosis/">management</a> of HIV/AIDS and associated opportunistic infections. The objective of this study is to estimate direct and indirect costs of managing HIV/AIDS to both the health sector and the patients, at Murtala Muhammad Specialist Hospital, Kano (MMSH). Patientsβ data from a sample of 256 adults and 28 children were collected between 1st January and 31st December 2010. The study revealed that majority of the patients were aged between 15 and 49 (87.7%), female (66.2%) and married (71.48%), while about forty percent were unemployed (39.8%) and 27.1% had an income of less N20,000. The average annual income for the patients was estimated to be N143,796. About half of the respondents had a CD4 count test done once (52.5%), most were on antiretrovirals (94.37%), a few had co-morbid illnesses (12.32%), side effects/adverse drug reactions (10.9%), hospitalized (11.27%) or had National Health Insurance Scheme (NHIS) coverage(3.87%). The estimated average total annual costs to the health sector and patients were N323,303 and N10,516 respectively. Major contributors to health sector costs which were all direct-medical costs were antiretroviral drugs (83.60%) and health care personnel (12.37%).<a target="_blank" rel="nofollow" href="https//www.modishproject.com/hiv-aids-knowledge-attitudes/"> Direct-medical costs to patients</a> amounted to about N3,055 (2.12%) with major contributions from hospitalisation , treatment of co-morbid illnesses and laboratory tests. Direct non-medical and indirect costs to patients were derived from transport (N2,634, 1.83%) and productivity loss (N4,827; 3.36%) respectively, the total patients cost of N10,516 amounted to 7.31% of their average annual income of N143,796. Thus, data obtained suggested that the management of HIV/AIDS at MMSH poses a serious economic burden on the health care system and on patients living with the disease. Majority of the health care costs (antiretrovirals) were provided by Non Governmental Organisations (NGOs); this scenario applies all over the country. In the event that the NGOs withdraw their aid in the future, the burden to the health sector may be too much for the Government to bear. The expansion of the NHIS to include HIV/AIDS management will decrease the burden on the Government and the patients. Increasing efforts on HIV infection prevention should also significantly decrease the burden of HIV/AIDS in the long run.</p><br> <br><p></p>
Project Overview
<p>
</p><p>l<a target="_blank" rel="nofollow" href="https://www.modishproject.com/campaign-management-hiv-aids-crisis/">Ill-health can resu</a>t in an increase in economic burden on individuals, contributing to income loss, asset depletion as well as investment of a large amount of National resources to combating that disease. These processes are brought into sharper focus by the social and economic impact of the human immunodeficiency virus/acquired <a target="_blank" rel="nofollow" href="https://www.modishproject.com/accessibility-health-system/">immunodeficiency</a> syndrome (HIV/AIDS) epidemic. Concern about the links between ill-health and impoverishment has placed health at the centre of development agencies‘ poverty reduction targets and strategies. This has strengthened arguments for a substantial increase in health sector investment to improve access for the world‘s poorest people to combat poverty as well as reduce disease burden (Russel, 2004). This thesis reports on an evaluation of costs committed to HIV/AIDS management in a secondary health facility, (MMSH) in Kano, Nigeria.</p><p><strong>1.2 Statement of Research Problem</strong></p><p>The HIV/AIDS pandemic constitutes one of the greatest health challenges of our time (IBBSS, 2008) and its impact cannot be overemphasized. HIV has added to the burden of the already over-stretched health care infrastructure in Nigeria as well as increased the number of orphans and other vulnerable children, placing additional strain on family and community support structures (FMOH, 2008).</p><p>With the growth rate (2%) and burden of illness, it is important for us to know the impact of HIV/AIDS management on health systems, individuals and societies as well as a description and analysis – a measure of the cost of illness (COI), which is a major tool in pharmacoeonomics. According to CDC (2009), COI is defined as the value of the resources that are expended or foregone as a result of a health problem. The COI includes health sector costs, the value of <a target="_blank" rel="nofollow" href="https://www.modishproject.com/knowledge-perception-risk/">lost productivity</a> by the patient (indirect cost), and the cost of pain and suffering (intangible costs) (CDC, 2009).</p>
<br><p></p>